Drug-drug Interaction Articles

Articles

Anticholinergic/Antimuscarinic Drug Prescribing for OAB: Caution is Needed
The possibility of drug–drug interactions is an important consideration with any medication, and particularly important in the older adult who are more likely to be using multiple medications. Also, this group is more likely to be taking other anticholinergic medications, and this “anticholinergic load” (the cumulative effect of taking multiple medications that have anticholinergic side effects) may potentiate the number and severity of side effects. Given the importance of the cholinergic system in cognition, direct impairment of cholinergic neurons may be the cause of these effects. In many older adults, OAB drug AC effects on cognition may go undetected.

Published November 30, -0001
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.

Apalutamide, an androgen receptor signaling inhibitor, in combination with androgen-deprivation therapy (ADT), is approved for treatment of patients with nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer, based on the data from the phase 3 SPARTAN and TITAN studies respectively.
Published February 14, 2022
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.

Ipatasertib is a selective, small molecule Akt inhibitor that is currently being developed for the treatment of metastatic castration-resistant prostate cancer. Darolutamide is an androgen receptor (AR) inhibitor that is approved for the treatment of non-metastatic castration-resistant prostate cancer.
Published November 2, 2022
Drug-Drug Interactions in Prostate Cancer Treatment.

Polypharmacy is associated with an increased risk of drug-drug interactions (DDIs), which can cause serious and debilitating drug-induced adverse events. With a steadily aging population and associated increasing multimorbidity and polypharmacy, the potential for DDIs becomes considerably important.
Published November 6, 2019
High Prevalence of Potential Drug-Drug Interactions in Patients with Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate: Beyond the Abstract
Abiraterone acetate (AA) is an oral anticancer agent used to treat metastatic castration resistant prostate cancer (mCRPC); clinically functioning to extend patient survival, and defer disease progression and symptoms^1,2. By inhibiting cytochrome P450 (CYP) 17A1, AA prevents androgen biosynthesis^3,4, while also serving to strongly inhibit CYP1A2, CYP2D6, and CYP2C8, and to moderately inhibit CYP3A4/5, CYP2C9, and CYP2C8. Given an increase in the prescription of oral anticancer agents⁵, and the typically elderly poly-morbid mCRPC patient population, there are heightened concerns regarding the potential of drug-drug interactions (DDIs) for men treated with AA. Specifically, DDIs may hinder the treatment efficacy of AA, or increase the risk of DDI associated adverse events (AEs). As up to 4% of patients with cancer are believed to experience fatal DDIs⁶, the primary aim of our retrospective review was to determine the frequency and severity of DDIs for mCRPC patients treated with AA.

Published November 22, 2016
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.

We hypothesized that pazopanib is an inhibitor of cisplatin renal transporters OCT2, MATE1 and MATE2-K based on previous studies demonstrating an interaction between tyrosine kinase inhibitors and these transporters.
Published May 19, 2016
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.

Clear cell renal cell carcinoma (ccRCC) is characterized by high histone deacetylase (HDAC) activity triggering both cell motility and the development of metastasis. Therefore, there is an unmet need to establish innovative strategies to advance the use of HDAC inhibitors (HDACIs).
Published November 3, 2020
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.

Coadministration of docetaxel and abiraterone acetate plus prednisone (AA + P) may benefit patients with metastatic castration-resistant prostate cancer (mCRPC) because of complementary mechanisms of action.

Published February 25, 2016

Drug-drug Interaction Articles

Articles

Login